Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 111
Filter
1.
Bone Marrow Transplant ; 49(7): 966-71, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24777184

ABSTRACT

We hypothesized that clinical risk factors could be identified within 2 weeks of onset of severe (stage 3 or 4) acute gut GVHD for identifying a patient population with a very poor outcome. Among 1462 patients who had allogeneic hematopoietic cell transplantation (HCT) between January 2000 and December 2005, 116 (7.9%) developed stage 3-4 gut GVHD. The median time for onset of stage 3-4 gut GVHD was 35 (4-135) days after allogeneic HCT. Eighty-five of the 116 patients (73%) had corticosteroid resistance before or within 2 weeks after the onset of stage 3-4 gut GVHD. Significant risk factors for mortality included corticosteroid resistance (hazards ratio (HR)=2.93; P=0.0005), age >18 years (HR=4.95; P=0.0004), increased serum bilirubin (HR 2.53; P=0.0001) and overt gastrointestinal bleeding (HR 2.88; P=0.0004). Among patients with stage 3-4 gut GVHD, the subgroup with 0, 1 or 2 risk factors had a favorable prognosis, whereas the subgroup with 3 or 4 risk factors had a dismal prognosis. This information should be considered in designing future studies of severe gut GVHD and in counseling patients about prognosis.


Subject(s)
Gastrointestinal Diseases/etiology , Graft vs Host Disease/etiology , Hematopoietic Stem Cell Transplantation/adverse effects , Adolescent , Adult , Aged , Child , Child, Preschool , Female , Gastrointestinal Diseases/immunology , Graft vs Host Disease/therapy , Hematopoietic Stem Cell Transplantation/methods , Humans , Infant , Male , Middle Aged , Prognosis , Risk Factors , Transplantation Conditioning/adverse effects , Transplantation Conditioning/methods , Transplantation, Homologous , Treatment Outcome , Young Adult
2.
Bone Marrow Transplant ; 47(7): 946-51, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22056644

ABSTRACT

The purpose of the study was to determine the long-term safety and effectiveness of high-dose immunosuppressive therapy (HDIT) followed by autologous hematopoietic cell transplantation (AHCT) in advanced multiple sclerosis (MS). TBI, CY and antithymocyte globulin were followed by transplantation of autologous, CD34-selected PBSCs. Neurological examinations, brain magnetic resonance imaging and cerebrospinal fluid (CSF) for oligoclonal bands (OCB) were serially evaluated. Patients (n=26, mean Expanded Disability Status Scale (EDSS)=7.0, 17 secondary progressive, 8 primary progressive, 1 relapsing/remitting) were followed for a median of 48 months after HDIT followed by AHCT. The 72-month probability of worsening ≥1.0 EDSS point was 0.52 (95% confidence interval, 0.30-0.75). Five patients had an EDSS at baseline of ≤6.0; four of them had not failed treatment at last study visit. OCB in CSF persisted with minor changes in the banding pattern. Four new or enhancing lesions were seen on MRI, all within 13 months of treatment. In this population with high baseline EDSS, a significant proportion of patients with advanced MS remained stable for as long as 7 years after transplant. Non-inflammatory events may have contributed to neurological worsening after treatment. HDIT/AHCT may be more effective in patients with less advanced relapsing/remitting MS.


Subject(s)
Hematopoietic Stem Cell Transplantation/methods , Immunosuppression Therapy/methods , Multiple Sclerosis/therapy , Adult , Antilymphocyte Serum/therapeutic use , Female , Humans , Immunosuppressive Agents/therapeutic use , Male , Middle Aged , Multiple Sclerosis/drug therapy , Multiple Sclerosis/pathology , Multiple Sclerosis/surgery , Transplantation, Autologous , Treatment Outcome , Whole-Body Irradiation
3.
Am J Transplant ; 9(5): 1037-47, 2009 May.
Article in English | MEDLINE | ID: mdl-19422333

ABSTRACT

Long-term survival after lung transplantation is limited by acute and chronic graft rejection. Induction of immune tolerance by first establishing mixed hematopoietic chimerism (MC) is a promising strategy to improve outcomes. In a preclinical canine model, stable MC was established in recipients after reduced-intensity conditioning and hematopoietic cell transplantation from a DLA-identical donor. Delayed lung transplantation was performed from the stem cell donor without pharmacological immunosuppression. Lung graft survival without loss of function was prolonged in chimeric (n = 5) vs. nonchimeric (n = 7) recipients (p < or = 0.05, Fisher's test). There were histological changes consistent with low-grade rejection in 3/5 of the lung grafts in chimeric recipients at > or =1 year. Chimeric recipients after lung transplantation had a normal immune response to a T-dependent antigen. Compared to normal dogs, there were significant increases of CD4+INFgamma+, CD4+IL-4+ and CD8+ INFgamma+ T-cell subsets in the blood (p < 0.0001 for each of the three T-cell subsets). Markers for regulatory T-cell subsets including foxP3, IL10 and TGFbeta were also increased in CD3+ T cells from the blood and peripheral tissues of chimeric recipients after lung transplantation. Establishing MC is immunomodulatory and observed changes were consistent with activation of both the effector and regulatory immune response.


Subject(s)
Lung Transplantation/immunology , Animals , Dogs , Flow Cytometry , Graft Rejection/immunology , Graft Rejection/pathology , Graft Survival/immunology , Graft Survival/physiology , Hematopoiesis , Hematopoietic Stem Cell Transplantation , Immunosuppressive Agents/therapeutic use , Lung Transplantation/physiology , Models, Animal , Respiratory Function Tests , T-Lymphocyte Subsets/immunology , Transplantation Chimera , Transplantation, Homologous
4.
Bone Marrow Transplant ; 44(11): 739-48, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19377515

ABSTRACT

We evaluated the pharmacokinetics and efficacy of oral mycophenolate mofetil (MMF) for treatment of refractory GVHD. In a prospective study of acute GVHD, 9 of 19 patients (47%) had a response and 10 (53%) had no improvement. Survival at 6 and 12 months after the start of MMF was 37 and 16%, respectively. In a retrospective study of acute GVHD, 14 of 29 patients (48%) had a response and 15 (52%) had no improvement. Survival at 6 and 12 months was 55 and 52%, respectively. In a prospective study of chronic GVHD, the cumulative incidence of disease resolution and withdrawal of all systemic immunosuppressive treatment was 9, 17 and 26% at 12, 24 and 36 months, respectively, after starting MMF. Thirteen patients (59%) required additional systemic immunosuppressive treatment for chronic GVHD. Nine of the 42 patients (21%) in the prospective studies discontinued MMF treatment because of toxicity. The area under the curve plasma concentrations of mycophenolic acid seemed to be suboptimal among patients with acute GVHD but not among those with chronic GVHD. MMF can be used effectively for treatment of GVHD.


Subject(s)
Graft vs Host Disease/drug therapy , Immunosuppressive Agents/therapeutic use , Mycophenolic Acid/analogs & derivatives , Administration, Oral , Adolescent , Adult , Child , Child, Preschool , Female , Graft vs Host Disease/blood , Graft vs Host Disease/metabolism , Humans , Immunosuppressive Agents/blood , Immunosuppressive Agents/pharmacokinetics , Male , Middle Aged , Mycophenolic Acid/blood , Mycophenolic Acid/pharmacokinetics , Mycophenolic Acid/therapeutic use , Prospective Studies , Retrospective Studies , Treatment Outcome , Young Adult
6.
Rheumatology (Oxford) ; 47(8): 1239-43, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18559373

ABSTRACT

OBJECTIVE: To characterize vascular lesions in SSc disease with high-resolution magnetic resonance angiography (Micro-MRA) of the finger. METHODS: Eight SSc subjects and eight age- and sex-matched healthy controls were recruited for this study. Among the SSc subjects, the mean +/- s.d. age was 54.5 +/- 4.9 yrs, and the mean +/- s.d. duration of disease was 8.3 +/- 8.4 yrs. The numbers of SSc subjects that had telangiectasia, calcinosis and impaired finger flexion were 3, 2 and 3, respectively. The 2D time-of-flight micro-MRA was performed on a 3T clinical MRI scanner using a custom-designed finger coil with an in-plane resolution of 0.16 x 0.21 mm(2) and slice thickness of 1.2 mm. The data for the proper palmar digital artery lumen area, the number of visible dorsal digital veins and a semi-quantitative vascular score, which evaluates the overall integrity of digital vessels, were independently evaluated by two experienced reviewers who were blinded to the status of the subject. RESULTS: Micro-MRA detected significant differences in the digital vasculature between SSc subjects and healthy volunteers. The SSc subjects had a significantly decreased digital artery lumen area (0.13 +/- 0.06 vs 0.53 +/- 0.26 mm(2), P < 0.001), a reduced number of digital veins (0.63 +/- 1.06 vs 3.13 +/- 0.99, P = 0.001) and a lowered overall vascular score (1.75 +/- 1.04 vs 3.5 +/- 0.53, P = 0.001). The study also found that both the digital artery lumen area (Pearson's; r = -0.72, P = 0.044) and vascular scores (Spearman's; rho = -0.75, P = 0.047) of the SSc subjects were inversely correlated with the duration of the disease. CONCLUSIONS: Micro-MRA can be used to identify and quantitatively characterize the vascular disease in SSc fingers. The parameters derived from micro-MRA could potentially be used as prospective biomarkers for clinical evaluation.


Subject(s)
Fingers/blood supply , Scleroderma, Systemic/pathology , Female , Humans , Magnetic Resonance Angiography/methods , Male , Microcirculation , Middle Aged , Observer Variation , Scleroderma, Systemic/physiopathology , Time Factors
7.
Gene Ther ; 14(21): 1549-54, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17805303

ABSTRACT

Several clinical studies of gene-modified T cells have shown limited in vivo function of the cells, immunogenicity of the transgene, and lack of a selective advantage for gene-modified T cells. To address these problems, we developed a lentiviral vector (LV) that provides a selectable, proliferative advantage and potentially decreases immunogenicity for transduced T cells. The bicistronic vector expressed two genes linked with an internal ribosomal entry site. One gene is a variant of the inosine monophosphate dehydrogenase 2, inosine monophosphate dehydrogenase (IMPDH(IY)), conferring resistance to the immunosuppressive drug mycophenolate mofetil (MMF). The other is a suicide gene, herpes simplex virus thymidine kinase (HSV-TK), rendering proliferating cells sensitive to ablation with ganciclovir, fused to the selectable transmembrane marker DeltaCD34 (DeltaCD34/TK). Cells transduced with LV-DeltaCD34/TK.IMPDH(IY) were efficiently enriched by immunomagnetic selection for CD34, proliferated in 0.5-5 microM MMF, and were killed by 0.5-25 microg ml(-1) ganciclovir. We demonstrate efficient selection and killing of gene-modified cells and suggest LV-DeltaCD34/TK.IMPDH(IY)-transduced T cells could be used to facilitate allogeneic hematopoietic cell engraftment. The expression of IMPDH(IY) would allow in vivo selection with MMF, and DeltaCD34/TK expression would allow rapid and safe elimination of transduced T cells if graft-versus-host disease developed.


Subject(s)
Genes, Transgenic, Suicide , Genetic Therapy/methods , Genetic Vectors/genetics , Herpesvirus 1, Human/enzymology , IMP Dehydrogenase/genetics , T-Lymphocytes , Thymidine Kinase/genetics , Antiviral Agents/therapeutic use , Cell Proliferation , Cloning, Molecular , Drug Resistance , Ganciclovir/therapeutic use , Genetic Engineering , Genetic Vectors/administration & dosage , Graft vs Host Disease/prevention & control , Hematopoietic Stem Cell Transplantation , Humans , IMP Dehydrogenase/metabolism , Immunomagnetic Separation/methods , Immunosuppressive Agents/pharmacology , K562 Cells , Mycophenolic Acid/analogs & derivatives , Mycophenolic Acid/pharmacology , T-Lymphocytes/cytology , T-Lymphocytes/drug effects , T-Lymphocytes/virology , Transduction, Genetic/methods , Transplantation, Homologous
8.
Vet Res Commun ; 30(8): 881-901, 2006 Nov.
Article in English | MEDLINE | ID: mdl-17139538

ABSTRACT

We have used a murine MSCV-based bicistronic retroviral vector, containing the common gamma chain (gammac) and enhanced green fluorescent protein (EGFP) cDNAs, to optimize retroviral transduction of canine cells, including an adherent canine thymus fibroblast cell line, Cf2Th, as well as normal canine CD34(+) bone marrow (BM) cells. Both canine cell types were shown to express Ram-1 (the amphotropic retroviral receptor) mRNA. Supernatants containing infectious viruses were produced using both stable (PA317) and transient (Phoenix cells) amphotropic virus producer cell lines. Centrifugation (spinfection) combined with the addition of polybrene produced the highest transduction efficiencies, infecting approximately 75% of Cf2Th cells. An average of 11% of highly enriched canine CD34(+) cells could be transduced in a protocol that utilized spinfection and plates coated with the fibronectin fragment CH-296 (Retronectin). Indirect assays showed the vector-encoded canine gammac cDNA produced a gammac protein that was expressed on the cell surface of transduced cells. This strategy may result in the transduction of sufficient numbers of CD34(+) BM cells to make the treatment of canine X-linked severe combined immunodeficiency and other canine genetic diseases feasible.


Subject(s)
Antigens, CD34/metabolism , Bone Marrow Cells/metabolism , Dogs , Genetic Vectors/genetics , Stem Cells/virology , Transduction, Genetic/veterinary , Animals , Cell Line , Fibroblasts , Genes/genetics , Mice , Retroviridae/genetics , Thymus Gland/cytology , Transduction, Genetic/methods
9.
Transplant Proc ; 38(5): 1638-40, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16797373

ABSTRACT

INTRODUCTION: While acute models of orthotopic lung transplantation have been described in dogs, the technical considerations of developing a survival model in this species have not been elaborated. Herein, we describe optimization of a canine survival model of orthotopic lung transplantation. METHODS: Protocols of orthotopic left lung transplantation and single lung ventilation were established in acute experiments (n=9). Four dogs, serving as controls, received autologous, orthotopic lung transplants. Allogeneic transplants were performed in 16 DLA-identical and 16 DLA-mismatched unrelated recipient dogs. Selective right lung ventilation was utilized in all animals. A Malecot tube was left in the pleural space connected to a Heimlich valve for up to 24 hours. To date, animals have been followed up to 24 months by chest radiography, pulmonary function tests, bronchoscopy with lavage, and open biopsies. RESULTS: Long-term survival was achieved in 34/36 animals. Two recipients died intraoperatively secondary to cardiac arrest. All animals were extubated on the operating table, and in all cases the chest tube was removed within 24 hours. Major complications included thrombosis of the pulmonary artery and subcritical stenosis of bronchial anastamosis. One recipient underwent successful treatment of a small bowel intussusception. CONCLUSIONS: We report our experience in developing a survival canine model of orthotopic single lung transplantation. While short-term survival following canine lung transplantation is achievable, we report particular considerations that facilitate animal comfort, early extubation, and lung reexpansion in the immediate postoperative period, further optimizing use of this species for experimental modeling of long-term complications after lung transplantation.


Subject(s)
Graft Survival/physiology , Lung Transplantation/physiology , Animals , Dogs , Graft Survival/immunology , Lung Transplantation/immunology , Lung Transplantation/veterinary , Models, Animal , Time Factors , Tissue and Organ Harvesting/methods , Tissue and Organ Harvesting/veterinary , Tissue and Organ Procurement/methods , Transplantation, Autologous , Transplantation, Homologous
10.
Mult Scler ; 12(2): 174-9, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16629420

ABSTRACT

Despite prolonged survival, patients with multiple sclerosis (MS) experience considerable morbidity, which adversely impacts quality of life. To assess the risk-benefit of a clinical trial of high dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation for MS, we sought to determine the natural history of the disease in a comparison group of untreated patients. We identified 285 individuals with 2132 combined observation years (median: 5.6 years; 5th to 95th percentile: 1-21 years), with Expanded Disability Status Scale (EDSS) scores of 3.0-5.5 at baseline observation. Disease-related mortality was zero at five years, 5.4% at 10 years, and 22% at 15 years (40 patients contributing to the data point; 95% confidence interval: 4-32%). Risk for progression to advanced disability, defined as an EDSS score of 8, was very low for the subgroup with a baseline EDSS score of 3-3.5; however, for those with a baseline EDSS score of 4-5.5, 3% had advanced disability after two years, 5% after three years, 6% after four years, 12% after five years, and 40% after 10 years. The estimated probability of disease progression, defined as an increase in EDSS score by > or = 1.0 sustained for at least 180 days, was 5% after one year, 14% after two years, 22% after three years, 38% after five years, 57% after 10 years, and >80% after 20 years of observation. The relevance of these features to the design of the clinical trial is discussed.


Subject(s)
Immunosuppressive Agents/therapeutic use , Multiple Sclerosis/physiopathology , Multiple Sclerosis/therapy , Stem Cell Transplantation , Clinical Trials as Topic , Combined Modality Therapy , Databases, Factual , Disabled Persons , Disease Progression , Female , Follow-Up Studies , Humans , Male , Multiple Sclerosis/mortality , Multiple Sclerosis, Relapsing-Remitting/mortality , Multiple Sclerosis, Relapsing-Remitting/physiopathology , Multiple Sclerosis, Relapsing-Remitting/therapy , Proportional Hazards Models , Regression Analysis , Research Design , Survival Analysis , Time Factors , Transplantation, Autologous
11.
Mult Scler ; 12(6): 824-5, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17263013

ABSTRACT

At a conference held in October 2005, participants presented studies on high dose immunosuppression with hematopoietic cell transplant (HCT) for multiple sclerosis (MS), including neuroimmunological and magnetic resonance imaging (MRI) mechanistic approaches, clinical registry reports, and ongoing or newly-designed protocols. A discussion panel considered questions on how to define success, timing of controlled clinical trials, difficulty in patient recruitment, and future direction of high dose therapy.


Subject(s)
Hematopoietic Stem Cell Transplantation/trends , Immunosuppression Therapy/trends , Multiple Sclerosis/therapy , Humans , Magnetic Resonance Imaging , Multiple Sclerosis/pathology , Registries
12.
Bone Marrow Transplant ; 32 Suppl 1: S77-80, 2003 Aug.
Article in English | MEDLINE | ID: mdl-12931249

ABSTRACT

Allogeneic hematopoietic stem cell transplantation (HSCT) tests the hypothesis that the replacement of a 'diseased' autoreactive immunological and stem cell compartment with one that is not autoreactive (but potentially alloreactive) can cure severe autoimmune diseases. The primary risks of allogeneic HSCT are the morbidity and morality associated with delayed immune reconstitution and GVHD. Although the risk of complications and mortality is greater than autologous HSCT, studies of allogeneic HSCT should be conducted in selected cases because there is a greater potential for sustained remissions. This review will discuss the anticipated results from allogeneic HSCT by summarizing outcomes in aplastic anemia and chronic myelogenous leukemia as well as a brief description of Seattle's experience with allogeneic HSCT in the first two patients with systemic sclerosis.


Subject(s)
Autoimmune Diseases/therapy , Hematopoietic Stem Cell Transplantation/methods , Autoimmune Diseases/complications , Autoimmune Diseases/mortality , Graft Rejection , Graft vs Host Disease/etiology , Hematopoietic Stem Cell Transplantation/adverse effects , Hematopoietic Stem Cell Transplantation/mortality , Humans , Scleroderma, Systemic/therapy , Transplantation Conditioning/adverse effects , Transplantation Conditioning/methods , Transplantation Conditioning/mortality , Transplantation, Homologous
13.
Bone Marrow Transplant ; 31(11): 1027-31, 2003 Jun.
Article in English | MEDLINE | ID: mdl-12774055

ABSTRACT

A dog model of stable mixed hematopoietic chimerism was established in which leukocyte-antigen-identical littermates receive nonmyeloablative total body irradiation before hematopoietic cell transplantation and postgrafting immunosuppression with mycophenolate mofetil and cyclosporine. Unmodified donor lymphocyte infusion (DLI) into stable mixed chimeras failed to increase donor chimerism, while DLI from donors sensitized to recipient minor-histocompatibility antigens promptly converted all recipients to complete donor chimerism. This established a model for studying approaches to enhance the graft-versus-host (GVH)-effect, a potential surrogate for graft-versus-leukemia activity. We asked if interleukin-2 (IL-2) given after unmodified DLI could result in reliable conversion to complete donor chimerism. IL-2, 4 x 10(5) IU/kg/day, was administered to six mixed chimeric dogs for 14 days. Four dogs received unmodified DLI with IL-2. At 20-40 weeks after DLI, all dogs remained mixed chimeras. For the two recipients of IL-2 only, mixed chimerism also remained unchanged. These results show that IL-2 given with DLI after nonmyeloablative transplantation in dogs is not effective in reliably converting mixed to complete donor chimerism.


Subject(s)
Hematopoietic Stem Cell Transplantation/methods , Interleukin-2/pharmacology , Lymphocyte Transfusion , Transplantation Chimera/immunology , Animals , Cyclosporine/therapeutic use , Dogs , Models, Animal , Transplantation Conditioning/methods , Whole-Body Irradiation
15.
Blood ; 98(13): 3868-70, 2001 Dec 15.
Article in English | MEDLINE | ID: mdl-11739201

ABSTRACT

This study compared the incidence of clinical extensive chronic graft-versus-host disease (GVHD), transplantation-related mortality, survival, and relapse-free survival among recipients randomly assigned to receive a 24-month or a 6-month course of cyclosporine prophylaxis after transplantation of allogeneic marrow from an HLA-identical sibling or alternative donor. Patients who did not have clinical manifestations of chronic GVHD on day 80 after transplantation were eligible for the study if they previously had acute GVHD or if a skin biopsy showed histologic evidence of chronic GVHD. Clinical extensive chronic GVHD developed in 35 of the 89 patients (39%) in the 24-month group and 37 of the 73 patients (51%) in the 6-month group. The hazard of developing chronic GVHD was not significantly different in the 2 groups (hazard ratio = 0.76; 95% confidence interval, 0.48-1.21; P =.25). In addition, there were no significant differences between the 2 groups in transplantation-related mortality, survival, or disease-free survival.


Subject(s)
Bone Marrow Transplantation , Cyclosporine/administration & dosage , Graft vs Host Disease/prevention & control , Adult , Biopsy , Bone Marrow Transplantation/mortality , Chronic Disease , Disease-Free Survival , Female , Graft vs Host Disease/pathology , Hematologic Neoplasms/therapy , Hematopoietic Stem Cell Transplantation , Humans , Male , Prospective Studies , Risk Factors , Skin/pathology , Survival Rate , Time Factors , Transplantation, Homologous
16.
Blood ; 98(13): 3505-12, 2001 Dec 15.
Article in English | MEDLINE | ID: mdl-11739150

ABSTRACT

The duration of immunodeficiency following marrow transplantation is not known. Questionnaires were used to study the infection rates in 72 patients surviving 20 to 30 years after marrow grafting. Furthermore, in 33 of the 72 patients and in 16 donors (siblings who originally donated the marrow) leukocyte subsets were assessed by flow cytometry. T-cell receptor excision circles (TRECs), markers of T cells generated de novo, were quantitated by real-time polymerase chain reaction. Immunoglobulin G(2) (IgG(2)) and antigen-specific IgG levels were determined by enzyme-linked immunosorbent assay. Infections diagnosed more than [corrected] 15 years after transplantation occurred rarely. The average rate was 0.07 infections per patient-year (one infection every 14 years), excluding respiratory tract infections, gastroenteritis, lip sores, and hepatitis C. The counts of circulating monocytes, natural killer cells, B cells, CD4 T cells, and CD8 T cells in the patients were not lower than in the donors. The counts of TREC(+) CD4 T cells in transplant recipients younger than age 18 years (at the time of transplantation) were not different from the counts in their donors. In contrast, the counts of TREC(+) CD4 T cells were lower in transplant recipients age 18 years or older, even in those with no history of clinical extensive chronic graft-versus-host disease, compared with their donors. The levels of total IgG(2) and specific IgG against Haemophilus influenzae and Streptococcus pneumoniae were similar in patients and donors. Overall, the immunity of patients surviving 20 to 30 years after transplantation is normal or near normal. Patients who received transplants in adulthood have a clinically insignificant deficiency of de novo-generated CD4 T cells, suggesting that in these patients the posttransplantation thymic insufficiency may not be fully reversible.


Subject(s)
Bone Marrow Transplantation/immunology , Bone Marrow Transplantation/mortality , Immunity , Adolescent , Adult , Antibodies, Bacterial/blood , B-Lymphocytes , CD4 Lymphocyte Count , CD8-Positive T-Lymphocytes , Child , Child, Preschool , Female , Flow Cytometry , Haemophilus influenzae/immunology , Humans , Immunoglobulin G/blood , Infections/epidemiology , Killer Cells, Natural , Leukocyte Count , Lymphocyte Count , Male , Monocytes , Polymerase Chain Reaction , Streptococcus pneumoniae/immunology , Surveys and Questionnaires , Time Factors , Tissue Donors , Transplantation, Homologous , Transplantation, Isogeneic
17.
Blood ; 98(12): 3447-55, 2001 Dec 01.
Article in English | MEDLINE | ID: mdl-11719387

ABSTRACT

Genetically modified donor T cells with an inducible "suicide" gene have the potential to improve the safety and availability of allogeneic hematopoietic stem cell transplantation by enhancing engraftment and permitting control of graft-versus-host disease (GVHD). However, several clinical studies of gene-modified T cells have shown limited to no in vivo function of the ex vivo expanded T cells. Using the well-established dog model of allogeneic marrow transplantation, the question was asked if retrovirally transduced, donor derived, ex vivo expanded cytotoxic T lymphocytes (CTLs) that are recipient specific could enhance engraftment of dog leukocyte antigen (DLA)-haploidentical marrow following a single dose of 9.2 Gy total body irradiation and no postgrafting immunosuppression. In this setting, only 4 of 11 control recipients of DLA-haploidentical marrow without added CTLs engrafted. CTLs did not enhance engraftment of CD34(+) selected peripheral blood stem cells. However, recipient-specific CTLs enhanced engraftment of DLA-haploidentical marrow in 9 of 11 evaluable recipients (P =.049). All dogs that engrafted developed multiorgan GVHD. To facilitate in vivo tracking, 8 dogs received CTLs transduced with a retroviral vector encoding green fluorescent protein (GFP) and neomycin phosphotransferase (neo). Recipients that engrafted had sharp increases in the numbers of circulating GFP(+) CTLs on days +5 to +6 after transplantation. GFP(+) CTLs isolated from blood were capable of recipient-specific lysis. At necropsy, up to 7.1% of CD3(+) cells in tissues were GFP(+) and polymerase chain reaction in situ hybridization for neo showed infiltration of transduced CTLs in GVHD-affected organs. These results show that ex vivo expanded, transduced T cells maintained in vivo function and enhanced marrow engraftment.


Subject(s)
Bone Marrow Transplantation , T-Lymphocytes, Cytotoxic/transplantation , Animals , Antigens, CD34/analysis , Cell Separation , Dogs , Gene Expression , Genetic Vectors , Graft Rejection , Graft Survival , Graft vs Host Disease/immunology , Green Fluorescent Proteins , HLA Antigens/analysis , Haplotypes , Histocompatibility , In Situ Hybridization , Kanamycin Kinase/genetics , Luminescent Proteins/genetics , Polymerase Chain Reaction , Retroviridae/genetics , T-Lymphocytes, Cytotoxic/immunology , T-Lymphocytes, Cytotoxic/metabolism , Transfection , Transplantation, Homologous , Whole-Body Irradiation
18.
Bone Marrow Transplant ; 28(1): 1-12, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11498738

ABSTRACT

We reviewed data from 24 transplant centers in Asia, Australia, Europe, and North America to determine the outcomes of stem cell collection including methods used, cell yields, effects on disease activity, and complications in patients with autoimmune diseases. Twenty-one unprimed bone marrow harvests and 174 peripheral blood stem cell mobilizations were performed on 187 patients. Disease indications were multiple sclerosis (76 patients), rheumatoid arthritis (37 patients), scleroderma (26 patients), systemic lupus erythematosus (19 patients), juvenile chronic arthritis (13 patients), idiopathic autoimmune thrombocytopenia (8 patients), Behcet's disease (3 patients), undifferentiated vasculitis (3 patients), polychondritis (1 patient) and polymyositis (1 patient). Bone marrow harvests were used in the Peoples Republic of China and preferred worldwide for children. PBSC mobilization was the preferred technique for adult stem cell collection in America, Australia, and Europe. Methods of PBSC mobilization included G-CSF (5, 10, or 16 microg/kg/day) or cyclophosphamide (2 or 4 g/m2) with either G-CSF (5 or 10 microg/kg/day) or GM-CSF (5 microg/kg/day). Bone marrow harvests were without complications and did not affect disease activity. A combination of cyclophosphamide and G-CSF was more likely to ameliorate disease activity than G-CSF alone (P < 0.001). g-csf alone was more likely to cause disease exacerbation than the combination of cyclophosphamide and g-csf (P = 0.003). Three patients died as a result of cyclophosphamide-based stem cell collection (2.6% of patients mobilized with cyclophosphamide). When corrected for patient weight and apheresis volume, progenitor cell yields tended to vary by underlying disease, prior medication history and mobilization regimen. Trends in the approaches to, and results of, progenitor cell mobilization are suggested by this survey. While cytokine-based mobilization appears less toxic, it is more likely to result in disease reactivation. Optimization with regard to cell yields and safety are likely to be disease-specific and prospective disease-specific studies of mobilization procedures appear warranted.


Subject(s)
Autoimmune Diseases/therapy , Hematopoietic Stem Cells/cytology , Adolescent , Adult , Antigens, CD34 , Autoimmune Diseases/complications , Cell Separation/methods , Child , Child, Preschool , Cyclophosphamide/administration & dosage , Cyclophosphamide/toxicity , Female , Global Health , Granulocyte Colony-Stimulating Factor/administration & dosage , Granulocyte Colony-Stimulating Factor/toxicity , Granulocyte-Macrophage Colony-Stimulating Factor/administration & dosage , Granulocyte-Macrophage Colony-Stimulating Factor/toxicity , Hematopoietic Stem Cell Mobilization/methods , Humans , Male , Middle Aged , Retrospective Studies , Risk Factors
19.
Front Biosci ; 6: G13-6, 2001 Aug 01.
Article in English | MEDLINE | ID: mdl-11487474

ABSTRACT

Conventional approaches to allogeneic stem cell transplantation have used toxic high-dose conditioning therapy to achieve allogeneic engraftment and control of underlying disease. For engraftment purposes, preclinical studies and clinical observations have shown that conditioning regimens can be markedly reduced in intensity, resulting in reduced treatment toxicities. Preclinical canine studies demonstrated that the use of potent pre- and postgrafting immunosuppression allows for reduction in conditioning regimens while facilitating development of stable mixed chimerism. If attenuated conditioning regimens can be successfully translated to human stem cell transplantation, an improved safety profile will allow potentially curative treatment to a more representative patient profile not currently offered such therapy. Mixed chimerism could prove curative of disease phenotype of various nonmalignant disturbances of the hematopoietic and immune systems. For patients with hematopoietic malignancy, spontaneous conversion to full donor hematopoeisis after stem cell transplant may prove curative by virtue of graft versus host reactions directed against the malignancy, however infusion of additional donor lymphocytes may be needed to treat persistent disease.


Subject(s)
Hematopoietic Stem Cell Transplantation/methods , Transplantation Conditioning/methods , Animals , Dogs , Graft vs Leukemia Effect , Hematologic Neoplasms/therapy , Humans , Transplantation Chimera , Transplantation Tolerance
20.
Ann N Y Acad Sci ; 938: 328-37; discussion 337-9, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11458521

ABSTRACT

Conventional allografting produces considerable regimen-related toxicities that generally limit this treatment to patients younger than 55 years and in otherwise good medical condition. T cell-mediated graft-versus-tumor (GVT) effects are known to play an important role in the elimination of malignant disease after allotransplants. A minimally myelosuppressive regimen that relies on immunosuppression for allogeneic engraftment was developed to reduce toxicities while optimizing GVT effects. Pre-transplant total-body irradiation (200 cGy) followed by post-transplant immunosuppression with cyclosporine (CSP) and mycophenolate mofetil (MMF) permitted human leukocyte antigen (HLA)-matched sibling donor hematopoietic cell engraftment in 82% of patients (n = 55) without prior high-dose therapy. The addition of fludarabine (90 mg/m2) facilitated engraftment in all 28 subsequent patients. Overall, fatal progression of underlying disease occurred in 20% of patients after transplant. Non-relapse mortality occurred in 11% of patients. Toxicities were low. Grade 2-4 acute graft-versus-host disease (GVHD) associated with primary engraftment developed in 47% of patients, and was readily controlled in all but two patients. Donor lymphocyte infusions (DLI) were not very effective at converting a low degree of mixed donor/host chimerism to full donor chimerism; however, the addition of fludarabine reduced the need for DLI. With a median follow-up of 244 days, 68% of patients were alive, with 42% of patients in complete remission, including molecular remissions. Remissions occurred gradually over periods of weeks to a year. If long-term efficacy is demonstrated, such a strategy would expand treatment options for patients who would otherwise be excluded from conventional allografting.


Subject(s)
Graft vs Tumor Effect/immunology , Hematopoietic Stem Cell Transplantation/methods , Transplantation Conditioning/methods , Adult , Animals , Clinical Trials, Phase I as Topic , Clinical Trials, Phase II as Topic , Cyclosporine/therapeutic use , Disease Progression , Dogs , Forecasting , Graft Enhancement, Immunologic/adverse effects , Graft Enhancement, Immunologic/methods , Graft Survival , Graft vs Host Disease/drug therapy , Graft vs Host Disease/etiology , Hematopoietic Stem Cell Transplantation/adverse effects , Histocompatibility , Humans , Immunosuppressive Agents/therapeutic use , Lymphocyte Transfusion , Methotrexate/therapeutic use , Middle Aged , Mycophenolic Acid/analogs & derivatives , Mycophenolic Acid/therapeutic use , Neoplasms/therapy , Prednisone/therapeutic use , Radiation Chimera , T-Lymphocytes, Cytotoxic/immunology , Tissue Donors , Transplantation Conditioning/adverse effects , Transplantation, Homologous , Treatment Outcome , Vidarabine/analogs & derivatives , Vidarabine/therapeutic use , Whole-Body Irradiation
SELECTION OF CITATIONS
SEARCH DETAIL
...